The clinical significance of FRAT1 and ABCG2 expression in pancreatic ductal adenocarcinoma

Tumor Biology

Volumn 36, Issue 12, 2015, Pages 9961-9968

  Yuan, Yuan ^a   Yang, Zhulin ^a   Miao, Xiongying ^a   Li, Daiqiang ^a   Liu, Ziru ^a   Zou, Qiong ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

ABCG2; Dysplasia; FRAT1; Immunohistochemistry; Pancreatic ductal adenocarcinoma; Pancreatic intraepithelial neoplasia

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; FREQUENTLY REARRANGED IN ADVANCED T CELL LYMPHOMA 1 PROTEIN; ONCOPROTEIN; UNCLASSIFIED DRUG; ABC TRANSPORTER; ABCG2 PROTEIN, HUMAN; FRAT1 PROTEIN, HUMAN; SIGNAL PEPTIDE; TUMOR MARKER; TUMOR PROTEIN;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; DYSPLASIA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; PANCREAS ADENOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL TIME; TUMOR DIFFERENTIATION; TUMOR INVASION; ADENOCARCINOMA; AGED; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; PANCREAS CARCINOMA; PATHOLOGY; PROGNOSIS;

ADENOCARCINOMA; AGED; ATP-BINDING CASSETTE TRANSPORTERS; BIOMARKERS, TUMOR; CARCINOMA, PANCREATIC DUCTAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS;

EID: 84952872845     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3752-0     Document Type: Article

References (29)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29.
2. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.
3. Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362:1605–17.
4. Löhr M. Is it possible to survive pancreatic cancer? Nat Clin Pract Gastroenterol Hepatol. 2006;3:236–7.
5. Cui J, Jiang W, Wang S, Wang L, Xie K. Role of Wnt/β-catenin signaling in drug resistance of pancreatic cancer. Curr Pharm Des. 2012;18:2464–71.
6. Schober M, Jesenofsky R, Faissner R, et al. Desmoplasia and chemoresistance in pancreatic cancer. Cancers (Basel). 2014;6:2137–54.
7. Freemantle SJ, Portland HB, Ewings K, et al. Characterization and tissue-specific expression of human GSK-3-binding proteins FRATl and FRAT2. Gene. 2002;291:17–27.
8. Yost C, Farr GH, Pierce SB, et al. GBP, an inhibitor of GSK-3, is implicated in Xenopus development and oncogenesis. Cell. 1998;93:1031–41.
9. Guo G, Kuai D, Cai S, et al. Knockdown of FRAT1 expression by RNA interference inhibits human glioblastoma cell growth, migration and invasion. PLoS ONE. 2013;8, e61206.
10. Zhang Y, Yu JH, Lin XY, et al. Overexpression of Frat1 correlates with malignant phenotype and advanced stage in human non-small cell lung cancer. Virchows Arch. 2011;459:255–63.
11. Wang Y, Liu S, Zhu H, et al. FRAT1 overexpression leads to aberrant activation of beta-catenin/TCF pathway in esophageal squamous cell carcinoma. Int J Cancer. 2008;123:561–8.
12. Wang Y, Hewitt SM, Liu S, et al. Tissue microarray analysis of human FRAT1 expression and its correlation with the subcellular localisation of beta-catenin in ovarian tumours. Br J Cancer. 2006;94:686–91.
13. Saitoh T, Katoh M. FRAT1 and FRAT2, clustered in human chromosome 10q24.1 region, are up-regulated in gastric cancer. Int J Oncol. 2001;19:311–5.
14. Jonkers J, Weening JJ, van der Valk M, et al. Overexpression of Frat1 in transgenic mice leads to glomerulosclerosis and nephrotic syndrome, and provides direct evidence for the involvement of Frat1 in lymphoma progression. Oncogene. 1999;18:5982–90.
15. Ni Z, Bikadi Z, Rosenberg MF, Mao Q. Structure and function of the human breast cancer resistance protein (BCRP/ABCG2). Curr Drug Metab. 2010;11:603–17.
16. Sarkadi B, Ozvegy-Laczka C, Német K, Váradi A. ABCG2 - a transporter for all seasons. FEBS Lett. 2004;567:116–20.
17. Campa D, Müller P, Edler L, et al. A comprehensive study of polymorphisms in ABCB1, ABCC2 and ABCG2 and lung cancer chemotherapy response and prognosis. Int J Cancer. 2012;131:2920–8.
18. Omran OM. The prognostic value of breast cancer resistance protein (BCRB/ABCG2) expression in breast carcinomas. J Environ Pathol Toxicol Oncol. 2012;31:367–76.
19. Zhang G, Wang Z, Luo W, et al. Expression of potential cancer stem cell marker ABCG2 is associated with malignant behaviors of hepatocellular carcinoma. Gastroenterol Res Pract. 2013;2013:782581.
20. Jiang Y, He Y, Li H, et al. Expressions of putative cancer stem cell markers ABCB1, ABCG2, and CD133 are correlated with the degree of differentiation of gastric cancer. Gastric Cancer. 2012;15:440–50.
21. Wang X, Xia B, Liang Y, et al. Membranous ABCG2 expression in colorectal cancer independently correlates with shortened patient survival. Cancer Biomark. 2013;13:81–8.
22. Mohelnikova-Duchonova B, Brynychova V, Oliverius M, et al. Differences in transcript levels of ABC transporters between pancreatic adenocarcinoma and nonneoplastic tissues. Pancreas. 2013;42:707–16.
23. Liu DC, Yang ZL, Jiang S. Identification of PEG10 and TSG101 as carcinogenesis, progression, and poor-prognosis related biomarkers for gallbladder adenocarcinoma. Pathol Oncol Res. 2011;17:859–66.
24. Olsen PA, Solberg NT, Lund K, et al. Implications of targeted genomic disruption of β-catenin in BxPC-3 pancreatic adenocarcinoma cells. PLoS ONE. 2014;9, e115496.
25. Zhi X, Tao J, Xie K, et al. MUC4-induced nuclear translocation of β-catenin: a novel mechanism for growth, metastasis and angiogenesis in pancreatic cancer. Cancer Lett. 2014;346:104–13.
26. Bilic J, Huang YL, Davidson G, et al. Wnt induces LRP6 signalosomes and promotes dishevelled-dependent LRP6 phosphorylation. Science. 2007;316:1619–22.
27. Van Amerongen R, Nawijn MC, Lambooij JP, et al. Frat oncoproteins act at the crossroad of canonical and noncanonical Wnt-signaling pathways. Oncogene. 2010;29:93–104.
28. Mohan A, Kandalam M. Ram kumar HL, et al. Stem cell markers: ABCG2 and MCM2 expression in retinoblastoma. Br J Ophthlmol. 2006;90:889–93.
29. Szczuraszek K, Materna V, Halon A, et al. Positive correlation between cyclooxygenase-2 and ABC-transporter expression in non-Hodgkin’s lymphomas. Oncol Rep. 2009;22:1315–23.